Serenno Medical

Company Overview

Snapshot

Founded in July 2017 by Noam Hadas, Serenno Medical operates with 1–10 employees. The company has raised $2.4 million across three funding rounds from three investors.

Business overview

Serenno Medical develops a novel method to monitor fluid balance and predict, identify, and avoid life-threatening complications like acute kidney injury (AKI) in intensive care unit (ICU) hospitalizations. Its core technology is a robust, hands-free, low-cost, and noninvasive device that provides accurate, continuous urine output measurements. The company serves the healthcare industry, focusing on hospitals and home care settings, and operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices.

Strategic signal

In January 2021, Elcam Medical invested $1.5 million in Serenno Medical, signaling strong commercial validation and strategic alignment for the company's kidney monitoring device. This investment from a producer of disposable medical devices suggests a potential pathway for market penetration and manufacturing scale, indicating a positive trajectory for Serenno Medical's product development and market adoption.

Company Intelligence Q&A

What is Serenno Medical's primary focus?

Serenno Medical is focused on developing a novel method to monitor fluid balance and predict, identify, and avoid common life-threatening complications in intensive care unit (ICU) hospitalizations, such as acute kidney injury (AKI).

When was Serenno Medical founded?

Serenno Medical was founded in July 2017.

What was a significant investment received by Serenno Medical in January 2021?

In January 2021, Elcam Medical invested $1.5 million in Serenno Medical for its kidney monitoring device.

Who is a co-founder of Serenno Medical?

Noam Hadas is a co-founder and CTO of Serenno Medical.